Changing paradigm in treatment of lung cancer
暂无分享,去创建一个
Abhishek Pathak | Anvesh Rathore | S. Viswanath | Sundaram Viswanath | Amul Kapoor | Bhupendra Nath Kapur | A. Pathak | A. Rathore | A. Kapoor | B. Kapur
[1] L. Tanoue,et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .
[2] Jeffrey W. Clark,et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.
[3] William Pao,et al. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors , 2006, Clinical Cancer Research.
[4] S. Gettinger,et al. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status , 2014 .
[5] Yasushi Totoki,et al. KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.
[6] M. Somerfield,et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cance , 2015, Journal of oncology practice.
[7] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[8] Mari Mino-Kenudson,et al. FGFR1 Amplification in Squamous Cell Carcinoma of The Lung , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] L. Sequist,et al. Genetic Changes in Squamous Cell Lung Cancer: A Review , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[11] A. Marchetti,et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Giaccone,et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.
[13] R. Rao,et al. Screening for EGFR mutations in lung cancer, a report from India. , 2011, Lung cancer.
[14] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[15] N. Hanna,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .
[16] Li Ding,et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. , 2008, Cancer research.
[17] T. Kohno,et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[19] R. Herbst,et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. , 2004, Lung cancer.
[20] T. Nakajima,et al. Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance , 1996, Japanese journal of cancer research : Gann.
[21] M. Ladanyi,et al. Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations , 2012, Clinical Cancer Research.
[22] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .
[23] Lachlan Standfield,et al. Histology as a treatment effect modifier in advanced non‐small cell lung cancer: A systematic review of the evidence , 2011, Respirology.
[24] C. Jameson. Report from India. , 1952, Journal of the American Medical Women's Association.
[25] B. Passlick,et al. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.